ArticleAlimentary pharmacology & therapeutics2013
Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease.
Article in Alimentary pharmacology & therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03590626 (Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease), which is not on this map. Cited by 74 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial
Who cites it
74 citing papers in PubMed, 1 synthesis or guideline pooled it, 127 citations in OpenAlex.
- Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD-A Systematic Review.International journal of molecular sciences · 2016Pooled it
- Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial).Diabetologia · 2020 · on this mapTrial
- MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial).Hepatology (Baltimore, Md.) · 2019Trial
- Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis.The Journal of clinical investigation · 2017Trial
- Assessment of treatment response in non-alcoholic steatohepatitis using advanced magnetic resonance imaging.Alimentary pharmacology & therapeutics · 2017Trial
- Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.Journal of hepatology · 2016Trial
- Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2015Trial
- MRI measurements of pancreatic fat content in the general population and their relationship with age, gender, and body mass index.Medicine · 2026Article
- Chronic Alcohol Consumption Induces Irreversible and Heterogeneous Pancreatic Steatosis in Men: An MRI-Based Cross-Sectional Study.Journal of clinical medicine · 2026Article
- Pancreatic steatosis is not associated with advanced steatohepatitis or fibrosis in metabolic dysfunction-associated steatotic liver disease.World journal of gastroenterology · 2025Article
- From NAFPD to MAFPD: a literature review of implications of a nomenclature change.Hepatobiliary surgery and nutrition · 2025Review
- Evaluation of Pancreatic Steatosis in Patients with Celiac Disease.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Article
- Understanding the association of intrapancreatic fat deposition with adiposity and components of metabolic syndrome in children and adolescents: a systematic review and meta-analysis.EClinicalMedicine · 2025Article
- Assessing Pancreatic Morphology via Endosonography in Alcohol-Induced Chronic Liver Disease.Sisli Etfal Hastanesi tip bulteni · 2025Article
- Non-invasive diagnosis of pancreatic steatosis with ultrasound images using deep learning network.Heliyon · 2024Article
- Correlation between Pancreatic Fat Deposition and Metabolic Syndrome: Relationships with Location in the Pancreas and Sex.Internal medicine (Tokyo, Japan) · 2024Article
- CT-based pancreatic radiomics predicts secondary loss of response to infliximab in biologically naïve patients with Crohn's disease.Insights into imaging · 2024Article
- Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease.JHEP reports : innovation in hepatology · 2024Article
- Pathophysiological Mechanisms and Clinical Associations of Non-Alcoholic Fatty Pancreas Disease.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
- Artificial intelligence assisted whole organ pancreatic fat estimation on magnetic resonance imaging and correlation with pancreas attenuation on computed tomography.Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2023Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundEctopic fat deposition in the pancreas and its association with hepatic steatosis have not previously been examined in patients with biopsy-proven non-alcoholic fatty liver disease (NAFLD).
aimTo quantify pancreatic fat using a novel magnetic resonance imaging (MRI) technique and determine whether it is associated with hepatic steatosis and/or fibrosis in patients with NAFLD.
methodsThis is a cross-sectional study including 43 adult patients with biopsy-proven NAFLD who underwent clinical evaluation, biochemical testing and MRI. The liver biopsy assessment was performed using the NASH-CRN histological scoring system, and liver and pancreas fat quantification was performed using a novel, validated MRI biomarker; the proton density fat fraction.
resultsThe average MRI-determined pancreatic fat in patients with NAFLD was 8.5% and did not vary significantly between head, body, and tail of the pancreas. MRI-determined pancreatic fat content increased significantly with increasing histology-determined hepatic steatosis grade; 4.6% in grade 1; 7.7% in grade 2; 13.0% in grade 3 (P = 0.004) respectively. Pancreatic fat content was lower in patients with histology-determined liver fibrosis than in those without fibrosis (11.2% in stage 0 fibrosis vs. 5.8% in stage 1-2 fibrosis, and 6.9% in stage 3-4 fibrosis, P = 0.013). Pancreatic fat did not correlate with age, body mass index or diabetes status.
conclusionsIn patients with NAFLD, increased pancreatic fat is associated with hepatic steatosis. However, liver fibrosis is inversely associated with pancreatic fat content. Further studies are needed to determine underlying mechanisms to understand if pancreatic steatosis affects progression of NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.